Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-9a5ac6d518a24ab2e0257a8b57ce793b"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-9a5ac6d518a24ab2e0257a8b57ce793b"/>
<resource>
<Composition>
<id value="composition-en-9a5ac6d518a24ab2e0257a8b57ce793b"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-9a5ac6d518a24ab2e0257a8b57ce793b"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-9a5ac6d518a24ab2e0257a8b57ce793b</b></p><a name="composition-en-9a5ac6d518a24ab2e0257a8b57ce793b"> </a><a name="hccomposition-en-9a5ac6d518a24ab2e0257a8b57ce793b"> </a><a name="composition-en-9a5ac6d518a24ab2e0257a8b57ce793b-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/15/1020/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - raxone</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/15/1020/001"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mp9a5ac6d518a24ab2e0257a8b57ce793b"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - raxone"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What Raxone is and what it is used for</li><li>What you need to know before you take Raxone</li><li>How to take Raxone</li><li>Possible side effects</li><li>How to store Raxone</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What raxone is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What raxone is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Raxone contains a substance called idebenone.</p><p>Idebenone is used to treat vision impairment in adults and adolescents with an eye disease called Leber s Hereditary Optic Neuropathy (LHON).</p><ul><li>This eye problem is inherited this means it runs in families.</li><li>It is caused by a problem with your genes (called a genetic mutation ) that affects the ability of cells in the eye to produce the energy they need to work normally, so they become inactive.</li><li>LHON can lead to loss of eyesight due to the inactivity of cells responsible for vision.</li></ul><p>Treatment with Raxone can restore the ability of cells to produce energy and so allow inactive eye cells to work again. This can lead to some improvement in lost eyesight.</p></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take raxone"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="2. What you need to know before you take raxone"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not take Raxone</p><ul><li>if you are allergic to idebenone or any of the other ingredients of this medicine (listed in<br/>section 6).</li></ul><p>Warnings and precautions<br/>Talk to your doctor or pharmacist before taking Raxone if:</p><ul><li>you have any blood, liver or kidney problems.</li></ul><p>Change in urine colour<br/>Raxone may make your urine become reddish brown. This change in colour is harmless it does not mean your treatment needs to change. However, the change in colour could mean that you have problems with your kidneys or bladder.</p><ul><li>Tell your doctor if your urine changes colour.</li><li>He or she may do a urine check to make sure the change in colour is not hiding other problems.</li></ul><p>Tests Your doctor will check your eye-sight before you start taking this medicine and then at regular visits while you are taking it.</p><p>Children and adolescents This medicine should not be used in children This is because it is not known if Raxone is safe or works in patients under 12 years of age.</p><p>Other medicines and Raxone Some medicines may interact with Raxone. Tell your doctor if you are taking, have recently taken or might take any other medicines, especially any of the following:</p><ul><li>antihistamines to treat allergies (astemizole, terfenadine)</li><li>to treat heartburn (cisapride)</li><li>to treat muscle and speech tics associated with Tourette syndrome (pimozide)</li><li>to treat hearth rhythm disorders (quinidine)</li><li>to treat migraine (dihydroergotamine, ergotamine)</li><li>to put you to sleep called anaesthetics (alfentanil)</li><li>to treat inflamation in rheumatoid arthritis and psoriasis (cyclosporine)</li><li>to prevent the rejection of an organ transplant (sirolimus, tacrolimus)</li><li>to treat strong pain called opioids (fentanyl)</li></ul><p>Pregnancy and breast-feeding<br/>If you are pregnant or breast-feeding, think you might be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><ul><li>Your doctor will prescribe Raxone to you only if the benefits of the treatment are greater than the risks to the unborn child.</li><li>Raxone may pass into the mother s milk. If you are breast-feeding your doctor will discuss with you whether to stop breast-feeding or to stop taking the medicine. This will take into account the benefit of breast-feeding to the child and the benefit of the medicine for you.</li></ul><p>Driving and using machines Raxone is not expected to affect your ability to drive or use machines.</p><p>Raxone contains lactose and sunset yellow (E110)</p><ul><li>Raxone contains lactose (a type of sugar). If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product..</li><li>Raxone contains a colourant called sunset yellow (also called E110). This may cause allergic reactions.</li></ul></div>
</text>
</section>
<section>
<title value="3. How to take raxone"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take raxone"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>How much to take The recommended dose is 2 tablets three times a day - this is a total of 6 tablets per day.</p><p>Taking this medicine</p><ul><li>Take the tablets with food - this helps to get more of the medicine from your stomach into your blood.</li><li>Swallow the tablets whole with a glass of liquid.</li><li>Do not crush or chew the tablets.</li><li>Take the tablets at the same time of day each day. For example in the morning at breakfast, with lunch at mid-day and with dinner in the evening.</li></ul><p>If you take more Raxone than you should If you take more Raxone than you should, talk to your doctor straight away.</p><p>If you forget to take Raxone If you forget a dose, skip the missed dose. Take the next dose at the usual time. Do not take a double dose to make up for a forgotten dose.</p><p>If you stop taking Raxone Talk to your doctor before you stop taking this medicine.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effect may happen with this medicine:</p><p>Very common (may affect more than 1 in 10 people):</p><ul><li>nasopharyngitis (cold)</li><li>cough</li></ul><p>Common (may affect up to 1 in 10 people):</p><ul><li>diarrhoea (mild to moderate that usually does not require discontinuation of treatment)</li><li>back pain</li></ul><p>Unknown frequency (frequency cannot be estimated from the available data):</p><ul><li>bronchitis</li><li>changes in blood test results: low level of white blood cells, or low level of red blood cells, or low level of platelets</li><li>increased cholesterol or fat in the blood shown in tests</li><li>fits, feeling confused, seeing or hearing things that are not real (hallucinations), feeling excited, movements that you cannot control, a tendency to wonder away, feeling dizzy, headache, feeling restless, dazed and unable to act or think normally</li><li>nausea, vomiting, loss of appetite, indigestion</li><li>high levels of some liver enzymes in the body which mean you have liver problems shown in tests, high levels of bilirubin this can make your skin and the whites of your eyes look yellow, hepatitis</li><li>rash, itching</li><li>pain in extremity</li><li>high levels of nitrogen in the blood - shown in tests change in urine colour</li><li>generally feeling unwell</li></ul><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system in Appendix V. By reporting side effecs you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store raxone"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store raxone"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and the bottle after EXP . The expiry date refers to the last day of that month.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Raxone contains</p><ul><li>The active substance is idebenone. Each film-coated tablet contains 150 mg of idebenone.</li><li>The other ingredients are: Tablet core: lactose monohydrate, cellulose microcrystalline, croscarmellose sodium, povidone K25, magnesium stearate and silica colloidal anhydrous. Tablet film-coating: macrogol, poly(vinyl alcohol), talc, titanium dioxide, sunset yellow (E110).</li></ul><p>What Raxone looks like and contents of the pack</p><ul><li>Raxone film-coated tablets are orange, round tablets of 10 mm diameter, engraved with the Santhera logo on one side and 150 on the other side.</li><li>Raxone is supplied in white plastic bottles. Each bottle contains 180 tablets.</li></ul><p>Marketing Authorisation Holder Chiesi Farmaceutici S.p.A. Via Palermo 26/A 43122 Parma Italy</p><p>Manufacturer Santhera Pharmaceuticals (Deutschland) GmbH Marie-Curie Strasse 8 79539 L rrach Germany Tel: +49 (0) 7621 1690 Email: <a href="mailto:office@santhera.com">office@santhera.com</a></p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Belgi /Belgique/Belgien Chiesi sa/nv<br/>T l/Tel: + 32 (0)2 788 42 Lietuva Chiesi Pharmaceuticals GmbH<br/>Tel: + 43 1 4073<br/>Chiesi Bulgaria EOOD<br/>Te .: + 359 29201Luxembourg/Luxemburg Chiesi sa/nv<br/>T l/Tel: + 32 (0)2 788 42 esk republika Chiesi CZ s.r.o.<br/>Tel: + 420 261221Magyarorsz g Chiesi Hungary Kft.<br/>Tel.: + 36-1-429 1Danmark Chiesi Pharma AB<br/>Tlf: + 46 8 753 35 Malta Chiesi Farmaceutici S.p.A.<br/>Tel: + 39 0521 2Deutschland Chiesi GmbH<br/>Tel: + 49 40 89724-0</p><p>Nederland Chiesi Pharmaceuticals B.V.<br/>Tel: + 31 88 501 64 Eesti Chiesi Pharmaceuticals GmbH<br/>Tel: + 43 1 4073Norge Chiesi Pharma AB<br/>Tlf: + 46 8 753 35<br/>Chiesi Hellas AEBE<br/>: + 30 210 6179 sterreich Chiesi Pharmaceuticals GmbH<br/>Tel: + 43 1 4073Espa a Chiesi Espa a, S.A.U.<br/>Tel: + 34 93 494 8Polska Chiesi Poland Sp. z.o.o.<br/>Tel.: + 48 22 620 1France Chiesi S.A.S.<br/>T l: + 33 1 47688Portugal Chiesi Farmaceutici S.p.A.<br/>Tel: + 39 0521 2Hrvatska Chiesi Pharmaceuticals GmbH<br/>Tel: + 43 1 4073Rom nia Chiesi Romania S.R.L.<br/>Tel: + 40 212023Ireland Chiesi Farmaceutici S.p.A.<br/>Tel: + 39 0521 2Slovenija CHIESI SLOVENIJA d.o.o.<br/>Tel: + 386-1-43 00 sland Chiesi Pharma AB<br/>S mi: +46 8 753 35 Slovensk republika Chiesi Slovakia s.r.o.<br/>Tel: + 421 259300Italia Chiesi Italia S.p.A.<br/>Tel: + 39 0521 2Suomi/Finland Chiesi Pharma AB<br/>Puh/Tel: +46 8 753 35<br/>Chiesi Farmaceutici S.p.A.<br/>: + 39 0521 2Sverige Chiesi Pharma AB<br/>Tel: +46 8 753 35 Latvija Chiesi Pharmaceuticals GmbH<br/>Tel: + 43 1 4073United Kingdom (Northern Ireland)<br/>Chiesi Farmaceutici S.p.A.<br/>Tel: + 39 0521 2This leaflet was last revised in</p><p>This medicinal product has been authorised under exceptional circumstances .<br/>This means that due to the rarity of the disease it has not been possible to obtain complete information on this medicinal product. The European Medicines Agency will review any new information which may become available every year and this leaflet will be updated as necessary.</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mp9a5ac6d518a24ab2e0257a8b57ce793b"/>
<resource>
<MedicinalProductDefinition>
<id value="mp9a5ac6d518a24ab2e0257a8b57ce793b"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mp9a5ac6d518a24ab2e0257a8b57ce793b"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mp9a5ac6d518a24ab2e0257a8b57ce793b</b></p><a name="mp9a5ac6d518a24ab2e0257a8b57ce793b"> </a><a name="hcmp9a5ac6d518a24ab2e0257a8b57ce793b"> </a><a name="mp9a5ac6d518a24ab2e0257a8b57ce793b-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/15/1020/001</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Raxone 150 mg film-coated tablets</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/15/1020/001"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName value="Raxone 150 mg film-coated tablets"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
